Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 10Esophageal Neoplasms 4Neoplasms 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Oesophago-gastric Cancer 1KRAS and NRAS Wild-type Colorectal Cancer 1Gliosarcoma 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Cone Dystrophy 3 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Breast Neoplasms 1Advanced Colorectal Cancer 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Panitumumab 1Gemcitabine 1Cystectomy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Cone Dystrophy 3 × Panitumumab × Clear all
NCT01916109 2016-02-12

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
4 enrolled 6 charts
Genitourinary

Cone Dystrophy 3, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡